Cyclic Peptide Integrin Antagonists for Selective α4β7 Inhibition

The peptide employs local quality by incorporating specific amino acid residues at defined positions (e.g., Xaa5 is N-Me-Arg, Xaa6 is Ser, Xaa7 is Asp) that create distinct binding characteristics for α4β7 versus α4β1. The cyclic structure with specific residue placement allows different regions of the molecule to interact selectively with α4β7 integrin while avoiding interference with α4β1, thereby achieving high selectivity without sacrificing efficacy.

The patent applies parameter changes by modifying the chemical structure of the integrin antagonist through cyclization and specific amino acid substitutions. The cyclic configuration and N-methylation of arginine residues alter the pharmacological parameters of the molecule, enabling it to distinguish between α4β7 and α4β1 integrins. These structural parameter changes result in high affinity binding to α4β7 while maintaining selectivity against α4β1, thus eliminating harmful side effects.

The patent merges the peptide chain into a cyclic structure by forming a bond between the C-terminus and N-terminus, creating a closed loop configuration. This cyclization merges the terminal groups into a unified structural element, preventing degradation and improving oral bioavailability. The cyclic dimer structure combines two monomer units linked through disulfide bonds, enhancing stability while maintaining synthesizability through established cyclic peptide methodology.

The invention uses composite material principles by creating a cyclic dimer structure composed of two peptide monomers linked through disulfide bonds. This composite configuration combines the properties of individual monomers while introducing enhanced stability and oral bioavailability through the cyclic architecture. The disulfide crosslinking creates a robust molecular framework that resists proteolytic degradation, thereby improving reliability without significantly complicating the synthesis process.